Wolfram Brugger
Overview
Explore the profile of Wolfram Brugger including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
52
Citations
2809
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
31.
Lubbert M, Ruter B, Claus R, Schmoor C, Schmid M, Germing U, et al.
Haematologica
. 2011 Nov;
97(3):393-401.
PMID: 22058219
Background: The treatment of acute myeloid leukemia of older, medically non-fit patients still poses a highly unmet clinical need, and only few large, prospective studies have been performed in this...
32.
Brugger W, Triller N, Blasinska-Morawiec M, Curescu S, Sakalauskas R, Manikhas G, et al.
J Clin Oncol
. 2011 Oct;
29(31):4113-20.
PMID: 21969500
Purpose: The phase III, randomized, placebo-controlled Sequential Tarceva in Unresectable NSCLC (SATURN; BO18192) study found that erlotinib maintenance therapy extended progression-free survival (PFS) and overall survival in patients with advanced...
33.
Sequist L, von Pawel J, Garmey E, Akerley W, Brugger W, Ferrari D, et al.
J Clin Oncol
. 2011 Jul;
29(24):3307-15.
PMID: 21768463
Purpose: c-MET (MET) receptor activation is associated with poor prognosis and epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) resistance in non-small-cell lung cancer (NSCLC). This global, randomized phase...
34.
Rittig S, Haentschel M, Weimer K, Heine A, Muller M, Brugger W, et al.
Mol Ther
. 2010 Dec;
19(5):990-9.
PMID: 21189474
The aim of this phase I/II nonrandomized trial was to assess feasibility, safety as well as immunological and clinical responses of a mRNA-based vaccination in patients with stage IV renal...
35.
Brugger W
Tumori
. 2010 Sep;
96(3):473-7.
PMID: 20845811
Aims And Background: There are only limited data on the safety and efficacy of panitumumab in patients who experienced severe infusion reactions during cetuximab antibody therapy. Case Report: We report...
36.
Cappuzzo F, Ciuleanu T, Stelmakh L, Cicenas S, Szczesna A, Juhasz E, et al.
Lancet Oncol
. 2010 May;
11(6):521-9.
PMID: 20493771
Background: First-line chemotherapy for advanced non-small-cell lung cancer (NSCLC) is usually limited to four to six cycles. Maintenance therapy can delay progression and prolong survival. The oral epidermal growth factor...
37.
Wagner K, Damm F, Gohring G, Gorlich K, Heuser M, Schafer I, et al.
J Clin Oncol
. 2010 Apr;
28(14):2356-64.
PMID: 20368538
Purpose: We assessed the prognostic impact of IDH1 R132 mutations and a known single nucleotide polymorphism (SNP) located in the same exon of the IDH1 gene in patients with cytogenetically...
38.
Kopp H, Wirths S, Faul C, Bethge W, Scheding S, Brugger W, et al.
J Cancer Res Clin Oncol
. 2010 Mar;
136(12):1921-7.
PMID: 20217128
Purpose: To determine the long-term outcome of patients after allogeneic transplantation of T-cell depleted versus unmanipulated hematopoietic stem cell grafts with respect to incidence of GvHD and overall survival in...
39.
Papakonstantinou G, Loeffler H, Haferlach T, Brugger W
Eur J Haematol
. 2010 Feb;
84(6):547-9.
PMID: 20113334
Erythroblastic synartesis is a very rare disorder, considered to be caused by autoimmune mechanisms, leading to aggregation of erythroid precursor cells in the bone marrow and subsequently to acquired dyserythropoiesis...
40.
Wierecky J, Muller M, Wirths S, Halder-Oehler E, Dorfel D, Schmidt S, et al.
Cancer Res
. 2006 Jun;
66(11):5910-8.
PMID: 16740731
A phase I trial was conducted to evaluate the feasibility, safety, and efficacy of a dendritic cell-based vaccination in patients with metastatic renal cell carcinoma (RCC). Autologous mature dendritic cells...